Peter C Lo1, Suzanne E Dahlberg2, Mizuki Nishino3, Bruce E Johnson1,4, Lecia V Sequist5, David M Jackman1,4, Pasi A Jänne1,4,6, Geoffrey R Oxnard1,4. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Department of Biostatistics, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts. 3. Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 4. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 5. Department of Medicine, Massachusetts General Hospital & Harvard Medical School, Boston, Massachusetts. 6. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
BACKGROUND:Erlotinib is a highly active epidermal growth factor receptor (EGFR) kinase inhibitor that is approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests that this drug may provide continued disease control after patients develop objective progression of disease (PD), although this has not been systematically studied to date. METHODS:Patients who had Response Evaluation CriteriaIn Solid Tumors-defined PD who were participating in 3 prospective trials of first-line erlotinib in advanced lung cancer were studied retrospectively, and the progression characteristics were compared between patients with and without EGFR-sensitizing mutations. Factors were studied that influenced the time until treatment change (TTC), defined as the time from PD to the start of a new systemic therapy or death. The rate of tumor progression was assessed by comparing tumor measurements between the computed tomography scan obtained at the time of PD and the preceding scan. RESULTS: In total, 92 eligible patients were studied, including 42 with and 50 without an EGFR-sensitizing mutation. The EGFR-mutant cohort had a slower rate of progression (P = .003) and a longer TTC (P < .001). Among the patients with EGFR-mutant cancers, 28 (66%) continued single-agent erlotinib after PD, and 21 (50%) were able to delay a change in systemic therapy for >3 months; only 2 patients received local debulking therapy during that period. Multivariate analysis of the patients with EGFR-mutant tumors demonstrated that a longer time to progression, a slower rate of progression, and a lack of new extrathoracic metastases were associated with a longer TTC. CONCLUSIONS: A change in systemic therapy commonly can be delayed in patients with EGFR-mutant lung cancer who objectively progress on first-line erlotinib, particularly in those with a longer time to progression, a slow rate of progression, and a lack of new extrathoracic metastases.
RCT Entities:
BACKGROUND:Erlotinib is a highly active epidermal growth factor receptor (EGFR) kinase inhibitor that is approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests that this drug may provide continued disease control after patients develop objective progression of disease (PD), although this has not been systematically studied to date. METHODS:Patients who had Response Evaluation Criteria In Solid Tumors-defined PD who were participating in 3 prospective trials of first-line erlotinib in advanced lung cancer were studied retrospectively, and the progression characteristics were compared between patients with and without EGFR-sensitizing mutations. Factors were studied that influenced the time until treatment change (TTC), defined as the time from PD to the start of a new systemic therapy or death. The rate of tumor progression was assessed by comparing tumor measurements between the computed tomography scan obtained at the time of PD and the preceding scan. RESULTS: In total, 92 eligible patients were studied, including 42 with and 50 without an EGFR-sensitizing mutation. The EGFR-mutant cohort had a slower rate of progression (P = .003) and a longer TTC (P < .001). Among the patients with EGFR-mutant cancers, 28 (66%) continued single-agent erlotinib after PD, and 21 (50%) were able to delay a change in systemic therapy for >3 months; only 2 patients received local debulking therapy during that period. Multivariate analysis of the patients with EGFR-mutant tumors demonstrated that a longer time to progression, a slower rate of progression, and a lack of new extrathoracic metastases were associated with a longer TTC. CONCLUSIONS: A change in systemic therapy commonly can be delayed in patients with EGFR-mutant lung cancer who objectively progress on first-line erlotinib, particularly in those with a longer time to progression, a slow rate of progression, and a lack of new extrathoracic metastases.
Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316
Authors: David M Jackman; Beow Y Yeap; Neal I Lindeman; Panos Fidias; Michael S Rabin; Jennifer Temel; Arthur T Skarin; Matthew Meyerson; Alison J Holmes; Ana M Borras; Boris Freidlin; Patricia A Ostler; Joan Lucca; Thomas J Lynch; Bruce E Johnson; Pasi A Jänne Journal: J Clin Oncol Date: 2007-01-16 Impact factor: 44.544
Authors: Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao Journal: Sci Transl Med Date: 2011-07-06 Impact factor: 17.956
Authors: Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller Journal: Clin Cancer Res Date: 2010-12-06 Impact factor: 12.531
Authors: Pasi A Jänne; Xiaofei Wang; Mark A Socinski; Jeffrey Crawford; Thomas E Stinchcombe; Lin Gu; Marzia Capelletti; Martin J Edelman; Miguel A Villalona-Calero; Robert Kratzke; Everett E Vokes; Vincent A Miller Journal: J Clin Oncol Date: 2012-04-30 Impact factor: 44.544
Authors: Andrew J Weickhardt; Benjamin Scheier; Joseph Malachy Burke; Gregory Gan; Xian Lu; Paul A Bunn; Dara L Aisner; Laurie E Gaspar; Brian D Kavanagh; Robert C Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Helena A Yu; Camelia S Sima; James Huang; Stephen B Solomon; Andreas Rimner; Paul Paik; M Catherine Pietanza; Christopher G Azzoli; Naiyer A Rizvi; Lee M Krug; Vincent A Miller; Mark G Kris; Gregory J Riely Journal: J Thorac Oncol Date: 2013-03 Impact factor: 15.609
Authors: Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz Journal: J Natl Cancer Inst Date: 2012-08-27 Impact factor: 13.506
Authors: Pasi A Jänne; Ana M Borras; Yanan Kuang; Andrew M Rogers; Victoria A Joshi; Hema Liyanage; Neal Lindeman; Jeffrey C Lee; Balazs Halmos; Elizabeth A Maher; Robert J Distel; Matthew Meyerson; Bruce E Johnson Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: S-H I Ou; P A Jänne; C H Bartlett; Y Tang; D-W Kim; G A Otterson; L Crinò; P Selaru; D P Cohen; J W Clark; G J Riely Journal: Ann Oncol Date: 2014-02 Impact factor: 32.976
Authors: Nicolas Marcoux; Scott N Gettinger; Grainne O'Kane; Kathryn C Arbour; Joel W Neal; Hatim Husain; Tracey L Evans; Julie R Brahmer; Alona Muzikansky; Philip D Bonomi; Salvatore Del Prete; Anna Wurtz; Anna F Farago; Dora Dias-Santagata; Mari Mino-Kenudson; Karen L Reckamp; Helena A Yu; Heather A Wakelee; Frances A Shepherd; Zofia Piotrowska; Lecia V Sequist Journal: J Clin Oncol Date: 2018-12-14 Impact factor: 44.544
Authors: Jessica J Lin; Stephanie Cardarella; Christine A Lydon; Suzanne E Dahlberg; David M Jackman; Pasi A Jänne; Bruce E Johnson Journal: J Thorac Oncol Date: 2015-12-25 Impact factor: 15.609
Authors: Benjamin L Lampson; Mizuki Nishino; Suzanne E Dahlberg; Danie Paul; Abigail A Santos; Pasi A Jänne; Geoffrey R Oxnard Journal: Cancer Date: 2016-08-15 Impact factor: 6.860
Authors: Geoffrey R Oxnard; Yuebi Hu; Kathryn F Mileham; Hatim Husain; Daniel B Costa; Philip Tracy; Nora Feeney; Lynette M Sholl; Suzanne E Dahlberg; Amanda J Redig; David J Kwiatkowski; Michael S Rabin; Cloud P Paweletz; Kenneth S Thress; Pasi A Jänne Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777